- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...
SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293 Stable ...
SHANGHAI, Aug. 30, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has ...
WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibility to meet various clients' needs in biologics development and manufacture. The platform can significantly ...
The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL It reduces viscosity by up to 90% while maintaining formulation ...
See how BioDlink’s digital-intelligence platform is driving three major improvements in lyophilization workflows.
CLEVELAND, Aug. 29, 2023 /PRNewswire/ -- IdentifySensors ® Biologics, a leading developer of digital diagnostic technologies, has partnered with Atlanta-based East West Manufacturing to produce ...
SAN DIEGO, Feb. 9, 2021 /PRNewswire/ — Nucleus Biologics™, The Cell Performance Company™, today announced the availability of NB-AIR™, the world’s first Artificial Intelligence Research platform for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback